Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (351-360 of 360) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 360 results.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2024
Guiding principles on the education and practice of theranosticsThomas N B Pascual, Diana Paez, Andrei Iagaru, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Reproducibility and Repeatability of Semiquantitative <sup>18</sup>F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter StudyHebert Alberto Vargas, Gem M Kramer, Andrew M Scott, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Research|February 6, 2021
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate CancerMargaret M Centenera, Julia S Scott, Jelle Machiels, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global InitiativeAkram Al-Ibraheem, Andrew M Scott, Ahmed Saad Abdlkadir, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Nature|July 3, 2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliveryAmanda X Y Chen, Kah Min Yap, Joelle S Kim, et al.
Nature|April 10, 2024
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJack D Chan, Christina M Scheffler, Isabelle Munoz, et al.
The Lancet. Oncology|October 3, 2024
Radiotherapy and theranostics: a Lancet Oncology CommissionMay Abdel-Wahab, Francesco Giammarile, Mauro Carrara, et al.
Pageof 36

Showing results (351-360 of 360) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 360 results.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2024
Guiding principles on the education and practice of theranosticsThomas N B Pascual, Diana Paez, Andrei Iagaru, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Reproducibility and Repeatability of Semiquantitative <sup>18</sup>F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter StudyHebert Alberto Vargas, Gem M Kramer, Andrew M Scott, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Research|February 6, 2021
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate CancerMargaret M Centenera, Julia S Scott, Jelle Machiels, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global InitiativeAkram Al-Ibraheem, Andrew M Scott, Ahmed Saad Abdlkadir, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Nature|July 3, 2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliveryAmanda X Y Chen, Kah Min Yap, Joelle S Kim, et al.
Nature|April 10, 2024
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJack D Chan, Christina M Scheffler, Isabelle Munoz, et al.
The Lancet. Oncology|October 3, 2024
Radiotherapy and theranostics: a Lancet Oncology CommissionMay Abdel-Wahab, Francesco Giammarile, Mauro Carrara, et al.
Pageof 36